Eagle Pharmaceuticals, Inc.

Please stand by.

Your program is about to begin. Good morning, everyone. My name is Reed, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceutical's third quarter 2020 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star and 1 on your touch-tone phone. As a reminder, this conference call is being recorded today, November 2nd, 2020. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Thank you, Reed. Welcome to Eagle Pharmaceuticals' third quarter earnings call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are EGLE's Chief Executive Officer, Scott Harris, David Pernoff, President and Chief Operating Officer, and our newly appointed Chief Financial Officer, Brian Cahill. This morning, the company issued a press release detailing financial results for the three-month sentence of September 30, 2020. This press release and a webcast of this call can be accessed through the Investors section of the EGLE website at EGLEUS.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagles Pharmaceuticals Management as of today and involve risks and uncertainties, including those noted in this morning's press release and are filed with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. A telephone replay will be available shortly after completion of this call. You'll find the dial-in information in today's press release. The archived webcast will be available for one year on our website at eagleus.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on November 2nd, 2020. Since then, EGLE may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to EGLE CEO, Scott Tariff.